154 related articles for article (PubMed ID: 1699619)
1. Newer approaches to the therapy of multiple myeloma.
Kyle RA
Blood; 1990 Nov; 76(9):1678-9. PubMed ID: 1699619
[No Abstract] [Full Text] [Related]
2. Pustular eruption at the site of subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor.
Passweg J; Buser U; Tichelli A; Gratwohl A; Speck B
Ann Hematol; 1991 Dec; 63(6):326-7. PubMed ID: 1836742
[No Abstract] [Full Text] [Related]
3. Multiple myeloma. New approaches to therapy.
Dunbar CE; Nienhuis AW
JAMA; 1993 May; 269(18):2412-6. PubMed ID: 7683062
[No Abstract] [Full Text] [Related]
4. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Jagannath S; Vesole DH; Glenn L; Crowley J; Barlogie B
Blood; 1992 Oct; 80(7):1666-72. PubMed ID: 1391937
[TBL] [Abstract][Full Text] [Related]
5. G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).
Joffe JK; Bell JB; Denham S; Adshead F; Millar JL; Millar BC
Exp Hematol; 1995 Apr; 23(4):376-82. PubMed ID: 7534716
[TBL] [Abstract][Full Text] [Related]
6. Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
Millar BC; Bell JB; Montes A; Millar JL; Maitland JA; Treleaven J; Viner C; Gore M; McElwain TJ
Br J Haematol; 1990 Jul; 75(3):366-72. PubMed ID: 2201402
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
[TBL] [Abstract][Full Text] [Related]
8. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
Barlogie B; Jagannath S; Dixon DO; Cheson B; Smallwood L; Hendrickson A; Purvis JD; Bonnem E; Alexanian R
Blood; 1990 Aug; 76(4):677-80. PubMed ID: 2200536
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human granulocyte colony-stimulating factor on neutrophil function in vitro and in vivo following chemotherapy and autologous bone marrow transplantation.
Humphreys JM; Rugman FP; Davies JM; Mimnagh P; Hart CA; Edwards SW
J Clin Lab Immunol; 1991 Feb; 34(2):55-61. PubMed ID: 1725883
[TBL] [Abstract][Full Text] [Related]
11. [Interferon as a sensitizing agent toward chemotherapy in a case of multiple myeloma refractory to treatment].
Seminara P; Codacci-Pisanelli G; Aronne T; Ercoli L; Avella A; Bonomo L
Recenti Prog Med; 1988 Oct; 79(10):415-6. PubMed ID: 3247510
[No Abstract] [Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
Lokhorst HM; Sonneveld P; Wijermans PW; van Marwijk Kooy M; Meuwissen OJ; van Oers RH; van der Griend R; Dekker AW
Br J Haematol; 1996 Jan; 92(1):44-8. PubMed ID: 8562409
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
Sallerfors B; Olofsson T; Lenhoff S
Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
[TBL] [Abstract][Full Text] [Related]
16. The role of colony-stimulating factors in bone marrow transplantation.
Sheridan WP
Cancer Invest; 1991; 9(2):221-8. PubMed ID: 1713805
[No Abstract] [Full Text] [Related]
17. Granulocyte and granulocyte-macrophage colony-stimulating factors.
Laplanche A
Lancet; 1993 Sep; 342(8872):678-9. PubMed ID: 7689678
[No Abstract] [Full Text] [Related]
18. Dose-intensified therapy combined with autologous blood stem cell support in patients with multiple myeloma.
Serke S; Kirsch A; Huhn D
Semin Oncol; 1994 Dec; 21(6 Suppl 16):29-32. PubMed ID: 7528448
[No Abstract] [Full Text] [Related]
19. [Multiple myeloma].
Imamura Y
Gan No Rinsho; 1989 Jan; Spec No():605-15. PubMed ID: 2644480
[No Abstract] [Full Text] [Related]
20. [Therapy of multiple myeloma and its complications].
Avvisati G; Pulsoni A; Petrucci MT; Tribalto M
Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
